Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.ebnl.org | |
Market Cap | 14.85 Cr. | |
Enterprise Value(EV) | 9.01 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.15 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 25.78 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 14.10 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 2.11 | Calculated using Price: 29.72 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.50 Cr. | 4,996,100 Shares |
FaceValue | 10 | |
About Emmessar Biotech & Nutrition Ltd. | ||
Emmessar Biotech & Nutrition Ltd., was originally started as Emmessar Chemical Industries Ltd on March 17,1992, for manufacturing Super Speciality Fine Chemicals. The Company succeeded in developing many Speciality Fine Chemicals in its own In-house R&D, which was recognised on January 15, 1996 by DSIR, Ministry of Science & Technology, Government of India, New Delhi . |
1 Day |
|
+2.02% |
1 Week |
|
+2.51% |
1 Month |
|
-26.50% |
3 Month |
|
+13.93% |
6 Month |
|
+20.80% |
1 Year |
|
+18.45% |
2 Year |
|
+11.80% |
5 Year |
|
+71.55% |
10 Year |
|
+575.34% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -7.98 | -40.75 | 78.73 | 36 | 16.42 | 19.4 | 29.1 | 8.01 | 7.85 | |
Return on Capital Employed (%) | -10.49 | -59.37 | 79.46 | 31.46 | 9 | 18.87 | 45.29 | 15.71 | 14.99 | |
Return on Assets (%) | -5.08 | -20.32 | 44.83 | 26.93 | 12.75 | 14.93 | 22.47 | 6.3 | 6.42 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 1 | 1 | 2 | 3 | 4 | 4 | 6 | 6 | 7 | 7 | |
Non Curr. Liab. | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | ||
Curr. Liab. | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 0 | |
Minority Int. | |||||||||||
Equity & Liab. | 2 | 2 | 3 | 4 | 5 | 5 | 7 | 8 | 8 | 8 | |
Non Curr. Assets | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Curr. Assets | 1 | 1 | 1 | 1 | 3 | 3 | 6 | 6 | 6 | 6 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2 | 2 | 3 | 4 | 5 | 5 | 7 | 8 | 8 | 8 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 2 | 2 | 3 | 1 | 1 | 3 | 7 | 0 | 1 | 1 | |
Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | |
Total Income | 2 | 2 | 4 | 3 | 2 | 5 | 8 | 2 | 3 | 3 | |
Total Expenditure | -2 | -2 | -2 | -2 | -1 | -4 | -6 | -1 | -2 | -2 | |
PBIDT | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | |
Interest | 0 | ||||||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Taxation | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | ||
Exceptional Items | -1 | 0 | 0 | ||||||||
PAT | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | |
Adjusted EPS | 0 | -1 | 2 | 2 | 1 | 2 | 3 | 1 | 1 | 1 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | ||
Cash Fr. Inv. | 0 | -1 | -1 | 0 | -1 | 0 | -3 | -1 | |||
Cash Fr. Finan. | |||||||||||
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Wed, 27 Mar 2024
Closure of Trading Window Pursuant to Clause 4 of Schedule B of PIT Regulations 2015 as amended the Trading Window of the company for dealing in securities will remain closed w.e.f. April 01 2024 till May 31 2024 for considering the Financial Results for the quarter/year ending March 31 2024. All insiders/designated persons their relatives are advised not to trade in the securities of the company during the above period. |
Wed, 20 Mar 2024
Board Meeting Outcome for Appointment Of Independent Director Pursuant to Reg 30 LODR Reg 2015 Mr. Dinesh Kumar Deora is appointed as Additional Independent Director w.e.f. 20.03.2024 |
Tue, 27 Feb 2024
Board Meeting Intimation for Appointment Of Independent Director EMMESSAR BIOTECH & NUTRITION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/03/2024 inter alia to consider and approve inducting / appointing an Independent Director on the Board of Directors |
Thu, 28 Mar 2024 |
High Delivery Percentage |
High Decrease in 1 Month |
High Increase in 3 Months |
CCI Bullish |
MFI Below 20 |